Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud
13th June 2025 Uncategorised 0Pfizer’s CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals.
More: Fierce Pharma Asia—Pfizer CEO talks bispecific deal; Otsuka's kidney disease win; Novartis-MSN Entresto feud
Source: fierce